2024-08-12-品牌价值-2024中国医药品牌价值和品牌强度评估报告（英）_35页_42mb

The Brand Finance special report on Chinese pharmaceutical brands for 2024 highlights key trends and top performers in the industry. China's pharmaceutical market is the world's second-largest, driven by factors like an aging population, digital health adoption, and growth in traditional Chinese medicine (TCM). Sinopharm leads with the highest brand value at $3.6 billion, while Guangzhou Pharmaceutical is ranked second at $2.5 billion and also holds the top position for TCM brands. Shanghai Pharmaceuticals occupies the third spot with $1.4 billion.

Brand strength is measured using the Brand Strength Index (BSI), with Tong Ren Tang scoring the highest at 80.9 out of 100 and receiving an AAA- rating. Consumer research indicates strong preference for TCM due to perceived natural ingredients and safety, with consumers often combining it with western medicine for health benefits. ESG initiatives are increasingly important, with brands engaging in sustainability projects to maintain public trust.

The methodology involves a comprehensive brand value chain analysis, incorporating market research, stakeholder perceptions, and financial metrics to assess brand value and strength, reflecting the evolving dynamics of the Chinese pharma sector.